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Emerging evidence suggests that metabolism influences immune cell sig-
naling and immunoregulation. To examine the immunoregulatory role
of glycolysis in pregnancy, we evaluated the properties of pyruvate
kinase in leukocytes from non-pregnant women and those with normal
pregnancy and pre-eclampsia.
Method of study
We evaluated pyruvate kinase expression in lymphocytes and neutroph-
ils from non-pregnant, pregnant, and pre-eclampsia patients using fluo-
rescence microscopy and flow cytometry. Leukocyte pyruvate kinase
activity and pyruvate concentrations were also evaluated. To study
pyruvate’s effect on signaling, we labeled Jurkat T cells with Ca2+ dyes
and measured cell responses in the presence of agents influencing intra-
cellular pyruvate.
Results
The expression of pyruvate kinase is reduced in lymphocytes and neu-
trophils from normal pregnant women in comparison with those of
non-pregnant women and pre-eclampsia patients. Similarly, the activity
of pyruvate kinase and the intracellular pyruvate concentration are
reduced in leukocytes of normal pregnant women in comparison with
non-pregnant women and women with pre-eclampsia. Using Jurkat
cells as a model of leukocyte signaling, we have shown that perturba-
tions of intracellular pyruvate influence Ca2+ signals.
Conclusion
Normal pregnancy is characterized by reduced pyruvate kinase expres-
sion within lymphocytes and neutrophils. We speculate that reduced
pyruvate kinase expression modifies immune cell responses due to
reduced pyruvate concentrations.
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Introduction
The immunological changes associated with preg-
nancy involve both local properties of the placenta
and broader systemic effects. For example, there is
an increase in severity of certain infections during
pregnancy.1–5 Moreover, it has been reported that
the spectrum of cytokines produced during preg-
nancy is skewed toward a Th2-type response.6–8
Interestingly, certain auto-immune diseases charac-
terized by Th1 responses, especially multiple sclerosis
and rheumatoid arthritis, have been reported to
remit during pregnancy then relapse post-partum.9–11
In contrast, lupus, which is a Th2-mediated disorder,
has been reported to worsen during pregnancy.12,13
To better understand these in vivo observations,
in vitro experiments have been performed. Impor-
tantly, reductions in microbial killing, chemotaxis,
respiratory burst activity, phagocytosis, and adhesion
have been reported for maternal leukocytes in
comparison with similarly treated cells from non-
pregnant women.14–20 However, the underlying
biochemical mechanisms responsible for these
immunomodulatory changes have not been
thoroughly described.
Recent studies have suggested that metabolic path-
ways, including metabolite concentrations, may con-
tribute to immunoregulation. Cross-talk between
metabolic processes and immune functions have
been described.21 We have previously proposed that
metabolism is itself a signal affecting cell behavior.22
Suttles and coworkers have demonstrated that fatty
acid-binding proteins affect leukocyte activation.23
More recently, a role for metabolism in the differen-
tiation of memory T cells has been reported.24,25 We
have recently shown that trophoblast contact, but
not tumor cell contact, reduces glucose transport in
neutrophils and, consequently, reduces cell activa-
tion.26 The regulation of glycolysis by signaling mol-
ecules or signaling by glycolytic intermediates is
most likely to occur at irreversible, rate-limiting met-
abolic steps, which are characterized by large free
energy changes. One of these steps is the conversion
of phosphoenolpyruvate by pyruvate kinase (EC
2.7.1.40) into pyruvate. Electrophysiological studies
have shown that pyruvate influences the activity of
store-operated Ca2+ release-activated Ca2+ (CRAC)
channels.27 The CRAC channel is a central regulator
of Ca2+ signaling in immune cells including lympho-
cytes, monocytes, mast cells, neutrophils, and oth-
ers.28 CRAC channels are activated by the release of
Ca2+ stored in the endoplasmic reticulum but are
rapidly inactivated by the accumulation of cytoplas-
mic Ca2+. Pyruvate blocks this negative feedback
effect of Ca2+ on CRAC channels, resulting in a pro-
longed Ca2+ influx.27 Thus, the glycolytic product
pyruvate is a prime candidate to regulate immune
cell Ca2+ signaling. This brings up the question of
how leukocytes regulate pyruvate levels without
seriously compromising energy production? Five key
pathways of regulating the glycolytic production of
pyruvate via pyruvate kinase are as follows: (i) the
availability of substrate, phosphoenolpyruvate, (ii)
covalent modification of pyruvate kinase (e.g., phos-
phorylation), (iii) feedback and feedforward mecha-
nisms, (iv) isotype switching, and (v) the
concentration of pyruvate kinase.
In the present study, we show that pyruvate
kinase expression, pyruvate kinase activity, and
pyruvate concentrations are substantially reduced in
leukocytes from pregnant women in comparison
with those of non-pregnant individuals. As leuko-
cytes from normal pregnant women exhibit some
anti-inflammatory characteristics,8–20 whereas leuko-
cytes from pregnancies complicated by pre-eclampsia
demonstrate certain characteristics associated with
inflammation,29–33 we further tested the properties
of pyruvate kinase in leukocytes of pre-eclampsia
patients. These experiments demonstrated increased
concentrations of pyruvate kinase in leukocytes from
pre-eclampsia patients in comparison with normal
pregnant women. We suggest that pyruvate kinase
expression contributes to immunoregulation during
pregnancy. We further speculate that pyruvate
kinase may act by influencing pyruvate concentra-
tions and calcium signaling, thus affecting the signal-
ing strength of transmembrane messengers and
modifying immune cell behavior.
Materials and methods
Study Design and Population
This cross-sectional study included women in the
following groups: (i) non-pregnant controls, (ii) nor-
mal pregnancy, and (iii) pre-eclampsia. Normal preg-
nant women were in their third trimester or term
not in labor, at ‡37 weeks of gestation (n = 21).
Patients with pre-eclampsia had hypertension (sys-
tolic blood pressure ‡140 mmHg or diastolic blood
pressure ‡90 mmHg on at least two occasions, 4 hr
to 1 week apart) associated with proteinuria
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(‡300 mg in a 24-hr urine collection or two dipstick
measurements of ‡1+ or one dipstick measurement
of ‡2+) (n = 25). Exclusion criteria of medical his-
tory included diabetes, chronic hypertension,
asthma, heart disease, thyroid disease, and autoim-
mune diseases; exclusion criteria for current preg-
nancy history included smoking, alcohol use, drugs,
active sexually transmitted diseases, group B
streptococcus colonization and any medications.
Patients with multiple gestations, pre-labor rupture
of membranes, histologic chorioamnionitis, stillbirth,
or fetal congenital or chromosomal abnormalities
were also excluded. All patients were enrolled by
the Perinatology Research Branch at the Hutzel
Women’s Hospital, Detroit, MI and provided written
informed consent prior to sample collection. The uti-
lization of samples for research purposes was
approved by the Institutional Review Boards of both
Wayne State University and the Eunice Kennedy
Shriver National Institute of Child Health and
Human Development (NICHD ⁄ NIH ⁄ DHHS).
These samples were subjected to cell isolation
followed by assessment of pyruvate kinase expression,
pyruvate kinase activity, and pyruvate concentration
using the instrumentation and procedures described
in the following paragraphs.
Materials
The following antibodies were used in this study:
rabbit polyclonal anti-pyruvate kinase M1 ⁄ M2
(Alpha Diagnostic International, San Antonio, TX,
USA; Chemicon ⁄ Millipore, Temecula, CA, USA),
goat polyclonal anti-lactate dehydrogenase (Chem-
icon ⁄ Millipore), Alexa Fluor 488-conjugated don-
key anti-rabbit IgG (Invitrogen Corp., Carlsbad, CA,
USA), and TRITC-conjugated donkey anti-goat
IgG (Sigma-Aldrich, St. Louis, MO, USA). Fura
Red-AM, Fluo-4-AM, Indo-1-AM, BAPTA-AM,
Pluronic-127, cell culture media, and phosphate-buf-
fered saline (PBS) were obtained from Invitrogen
Corp. Lipopolysaccharide (LPS; cat. no. L2762) and
phytohemaggulutinin (PHA) were obtained from
Sigma-Aldrich. All other chemicals were purchased
from Sigma-Aldrich.
Cell Isolation
Cells were isolated by discontinuous density gradient
centrifugation. Briefly, 6 mL of blood anticoagulated
with EDTA were layered over 3.5 mL Histopaque
1077 and 3.5 mL Histopaque 1119 (Sigma-Aldrich)
and centrifuged at 300 · g for 45 min at room tem-
perature. After centrifugation, peripheral blood
mononuclear cells (PBMCs) were collected from the
interface between the plasma and Histopaque 1077
layers. The cells were then washed with PBS. CD3+
cells were isolated with human T cell enrichment kit
(StemCell Technologies, Vancouver, BC, Canada).
Briefly, 5 · 107 ⁄ mL PBMCs were mixed with 50 lL
T cell enrichment cocktail and then incubated at
room temperature for 10 min. Magnetic nanoparti-
cles (50 lL) were added to the cell mixture and
incubated at room temperature for 10 min. Magneti-
cally labeled cells were then separated from the
unlabeled CD3+ cells by using a magnet supplied
with the kit.
Flow Cytometry
To measure pyruvate kinase expression in leuko-
cytes, whole blood (100 lL) anticoagulated with
EDTA was incubated for 30 min at 4C with r-phy-
coerythrin-conjugated anti-CD3 antibody (clone
SK7; BD Biosciences, San Jose, CA, USA). Red blood
cells were lysed by incubation with FACS Lysing
Solution (BD Biosciences), pelleted by centrifugation
at 300 · g for 5 min at 4C, and washed two times
with Dulbecco’s PBS (D-PBS) prior to fixation with
1% paraformaldehyde in PBS for 30 min at room
temperature. Following fixation, leukocytes were
washed two times with 3% FBS in D-PBS. Cells
were suspended in permeabilization medium (Med-
ium B; Invitrogen) and incubated with polyclonal
goat anti-pyruvate kinase (Chemicon ⁄ Millipore),
polyclonal goat anti-lactate dehydrogenase (Chem-
icon ⁄ Millipore), or purified goat IgG as an isotype
control (Invitrogen) all at a final concentration of
100 lg ⁄ mL for 30 min at 4C. Incubation was termi-
nated by the addition of 3% FBS in D-PBS. Cells
were pelleted by centrifugation at 300 · g for 5 min
at 4C, and washed once with 3% FBS in D-PBS.
This was followed by suspension in permeabilization
medium and the addition of Alexa Fluor 488-conju-
gated donkey anti-goat IgG (final concentration
4 lg ⁄ mL; Invitrogen). Cells were incubated at 4C
for 15 min. Incubation was again terminated by add-
ing 3% FBS in D-PBS followed by washes with 3%
FBS in D-PBS and D-PBS, respectively. Stained cells
were finally suspended in 0.1% paraformaldehyde in
PBS for flow cytometric acquisition of CD3+ lympho-
cytes (gated using anti-CD3-PE versus side-scatter
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dot plot) or neutrophils (gated on forward versus
side-scatter properties). All acquisitions and analyses
were performed with a FACSCalibur flow cytometer
and CellQuest Pro software, version 5.2.1 (BD Bio-
sciences). Pyruvate kinase, lactate dehydrogenase,
and isotype control fluorescence intensities were
recorded as the median fluorescence intensity (MFI).
The fluorescence intensities of isotype control anti-
bodies were subtracted from pyruvate kinase and
lactate dehydrogenase fluorescence intensities prior
to statistical analyses.
Pyruvate Kinase Activity Assay
Frozen lymphocyte pellets were sonicated for 30 s and
centrifuged at 15,000 · g for 10 min. Aliquots of the
supernatant were assayed for pyruvate kinase activity
using a fluorescence-coupled assay. One milliliter
reaction buffer (50 mm Tris–HCl pH 7.4, 225 mm KCl,
12 mm MgCl2, 0.6 mm ADP, 4.3 mm phospho
enolpyruvate (PEP), 0.6 mm NADH, and 4 IU l-lactate
dehydrogenase) was incubated in a spectrophotome-
ter for 5 min to achieve temperature equilibrium and
to determine the blank reading. The reaction was ini-
tiated by adding 33 lL of a sample aliquot into the
cuvette. The decrease in A340 nm was recorded for
5 min. Protein concentrations were determined using
the Bio-Rad protein assay (Bio-Rad, Hercules, CA,
USA). Pyruvate kinase activity was calculated using
DA340 ⁄ min obtained from the initial linear portion of
the curve and normalized to sample’s protein
concentration according to the equation:




Pyruvate was measured in PBMCs as described.34 As
cell washing procedures may influence intracellular
pyruvate levels, the extracellular volume in cell pel-
lets was measured by adding fluorescein–dextran
(Mr = 40,000) to the cell suspension as a marker for
the extracellular compartment (0.5 mg ⁄ mL final
concentration). Samples were centrifuged at 600 · g
followed by aspiration of the supernatant. The pellet
was extracted with 0.25 mL of ice-cold 0.5 m HClO4
then incubated on ice for 10 min. The mixture was
neutralized with 24 lL of 2.5 m K2CO3. As Amplex
Red is pH-sensitive, the pH was carefully checked at
this step. After centrifugation at 10,000 · g for
5 min, the supernatant was collected for pyruvate
measurement. Briefly, 20 lL of standards or extrac-
tion samples were pipetted into a 96-well fluores-
cence black plate (Corning Inc., Corning NY, USA),
180 lL of the assay solution was added into each
well and then incubated for 30 min at room temper-
ature. The final reaction solution contained 200 mm
potassium phosphate with 1.0 mm EDTA, pH 6.7,
1.0 mm MgCl2, 10 lm FAD, 0.2 mm thiamine pyro-
phosphate, 0.2 U ⁄ mL pyruvate oxidase, 50 lm
amplex red, and 0.2 U ⁄ mL HRP. Fluorescence at
590 nm was measured with excitation at 535 nm.
Background was corrected by subtracting the value
of the zero pyruvate control from sample readings.
Using excitation and emission wavelengths of 485
and 530 nm, the intensity of fluorescein was mea-
sured then compared to a fluorescein–dextran con-
centration calibration curve to calculate the
extracellular volume of the pellet, which permitted
the accurate determination of the intracellular pyru-
vate concentration.
Cell Labeling for Ca2+ Experiments
Human Jurkat T cells were incubated with 5.5 lm
Fura Red-AM, 2.6 lm Fluo-4-AM, and 2% Pluronic-
127 in PBS for one hour at 37C.35 After incubation,
cells were washed with PBS, resuspended in cell
buffer (150 mm NaCl, 4 mm KCl, 25 mm HEPES,
3 mm CaCl2, 10 mm glucose, and 1 mg ⁄ mL BSA,
pH7.6) and incubated for further 30 min at 37C, to
purge excess dye. Cells were washed with cell buffer
before use. For experimental studies, 10 mm phenyl-
alanine or 5 mm pyruvate were added for 15 min at
37C before readings. Cells were stimulated with
10 lg ⁄ mL PHA with or without test compounds for
15 min at 37C then used in experiments. Fluores-
cence measurements were performed with a Flexsta-
tion device (Molecular Devices, Inc., Sunnyvale, CA,
USA) with excitation at 465 nm and detection at
657 nm for Fura Red and 516 nm for Fluo-4.
Fluorescence Microscopy
Fluorescence microscopy was performed using a 20·
objective in a Nikon microscope (model E800;
Melville, NY, USA). Images were collected using an
Andor (Belfast, Northern Ireland) iXon EMCCD
(electron multiplying charge-coupled device) camera
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with the following settings: digitizer, 16 bit (1 MHz);
vertical speed shift, 1.7 (ls ⁄ pixel); exposure time,
0.5 s; EM gain, 150; pre-amplifier gain, 2.4·; tem-
perature of EMCCD chip, )90C. Micrographs were
recorded using MetaMorph software (version
7.1.2.0; Molecular Devices).
Statistical Analyses
Statistical analyses were performed using unpaired
t-tests to evaluate the null hypothesis.
Results
Qualitative Analysis of Pyruvate Kinase
Expression
As cell metabolism has been linked with signal trans-
duction and immunoregulation,21–26 we have evalu-
ated the potential role of pyruvate kinase, which
catalyzes a key rate-limiting step of glycolysis, in leu-
kocyte properties during pregnancy. To provide a
preliminary evaluation of pyruvate kinase, we
employed immunofluorescence microscopy to exam-
ine its expression in CD3+ lymphocytes of non-preg-
nant women, pregnant women, and pre-eclampsia
patients. As illustrated in Fig. 1, pyruvate kinase can
be found throughout cells, although it is most highly
expressed at the cell periphery. No differences in the
cytoplasmic distribution of this enzyme was detected
when examining leukocytes from non-pregnant
women, normal pregnant women, and those with
pre-eclampsia. These findings are consistent with our
previous observations.36 However, upon closer
inspection of the cell populations, it appeared that
the leukocyte samples from pregnant women were
substantially dimmer than those of non-pregnant
individuals or pre-eclampsia patients. To test this
finding using a different technique, extracts of CD3+
lymphocytes were prepared then subjected to SDS-
PAGE ⁄ Western blotting. These experiments showed
that pyruvate kinase expression is significantly
reduced in samples from pregnant women (Fig. S1).
To control for sample loading, the blots were
stripped and reblotted using actin as a control (data
not shown). Thus, pyruvate kinase expression is
reduced during normal pregnancy, but its intracellu-
lar distribution is unaffected.
Quantitative Flow Cytometric Analysis of Pyruvate
Kinase Expression
Flow cytometry was used to provide compelling
quantitative data concerning pyruvate kinase expres-
sion by leukocyte populations. Fig. 2 shows repre-
sentative flow cytometry histograms of pyruvate
kinase labeling experiments and isotype controls for
CD3+ lymphocyte samples from non-pregnant
women and normal pregnant women. To exclude
other cell types, anti-CD3-phycoerthrin was used in
gated detection (see Fig. 2 insert). As shown in
Fig. 2a, pyruvate kinase expression is substantially
reduced in samples from pregnant women in com-
parison with non-pregnant women. However, the
expression of lactate dehydrogenase was not signifi-
cantly altered by pregnancy (Fig. 2b).
To evaluate the broad significance of reduced
pyruvate kinase expression, we used flow cytometry
to measure pyruvate kinase and lactate dehydroge-
nase levels in CD3+ lymphocytes from populations of
non-pregnant and normal pregnant women as well
as in those with pre-eclampsia (Fig. 3a). Lymphocyte
pyruvate kinase levels were reduced in normal preg-
nancies in comparison with non-pregnant women
(a) (b) (c)
Fig. 1 Fluorescence microscopy of pyruvate kinase. CD3+ lymphocytes were prepared from peripheral blood samples obtained from non-pregnant
women (a), pregnant women (b), and pre-eclampsia patients (c). Cells were labeled with an anti-pyruvate kinase antibody. Images were collected
under identical conditions, as described in the Materials and Methods (Bar = 10.6 mm).
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(P = 0.00001; n = 10 for both groups). However,
pyruvate kinase levels of lymphocytes from pre-
eclampsia patients were greater than those of normal
pregnant women (P = 0.00046; n = 10), but indistin-
guishable from those of non-pregnant women (see
also Fig. S2). In contrast, no significant changes in
lactate dehydrogenase were detected. To ascertain
whether these changes in CD3+ lymphocytes were
found among other leukocyte populations, neu-
trophils were also evaluated (Fig. 3b). Neutrophils
were separately cataloged based upon their 90
light-scattering properties. As neutrophils are larger
than lymphocytes, they express more pyruvate
kinase. Nonetheless, a similar pattern of highly sig-
nificant changes in pyruvate kinase expression was
noted, with a reduction in expression during normal,
but not pre-eclamptic, pregnancy. The expression of
neutrophil lactate dehydrogenase was not influenced
by pregnancy. Thus, pyruvate kinase expression is
reduced in maternal leukocytes during normal preg-
nancy.
We have noted that pyruvate kinase expression is
substantially higher in leukocytes from pre-eclamp-
sia patients than those of normal pregnant mothers.
As pre-eclampsia exhibits some characteristics of
inflammation,29,30 we considered the possibility that
inflammatory signaling increases the expression of
this enzyme. Fig. 4 shows flow cytometry histograms
of leukocytes stained with an anti-pyruvate kinase
antibody or an isotype-matched control reagent. As
these data show, LPS (100 ng ⁄ mL, 30 min) had no
effect on the level of pyruvate kinase expression by
neutrophils.
Evaluation of Enzymatic Activity and Product
Levels
To verify that enzyme expression levels correlate
with enzyme activity, we measured pyruvate kinase
activity in lymphocyte extracts. Pyruvate kinase
activity was measured as described in the Materials
and Methods and illustrated in Fig. 5. Pyruvate
kinase activity in leukocyte samples from normal
pregnant women was 23 ± 4 DA ⁄ min ⁄ mg protein
(mean ± S.D.; n = 8) in comparison with 40 ± 9
DA ⁄ min ⁄ mg protein (n = 7) for non-pregnant
women (P < 0.001). Although the pyruvate kinase
activity of leukocytes from pre-eclampsia patients
(45 ± 22 DA ⁄ min ⁄ mg protein; n = 6) was similar to
that of samples from non-pregnant women, it was
significantly greater than that found for normal
pregnancy samples (P < 0.029). As observed in these
studies and the flow cytometry experiments (Fig. 3),
leukocytes from women with pre-eclampsia demon-
strated greater variability in these measures than did
cells from non-pregnant or normal pregnant women.
As expected based upon the flow cytometry studies,
these enzyme activity measurements showed that
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Fig. 2 Flow cytometry histograms of pyruvate kinase abundance in
human CD3+ lymphocytes are shown. Panel a: Representative histo-
grams showing pyruvate kinase or isotype control labeling are shown.
Pyruvate kinase expression is reduced in maternal lymphocytes (black
dashed line) relative to lymphocytes from non-pregnant adults (black
solid line). Fluorescence histograms of cells stained with an isotype
control antibody are shown in gray (dashed line = maternal;
solid = normal adult). Only CD3+ cells are shown in the histograms
(see inset showing CD3 PE versus side-scatter dot plot). Panel b: Rep-
resentative histogram overlay of cells stained with an anti-lactate
dehydrogenase or isotype control antibodies. Samples from pregnant
women (black dashed line) and non-pregnant women (black solid line)
are shown. Isotype controls are shown in gray on the left-hand side
levels between maternal blood and normal adult peripheral blood
CD3+ lymphocytes (dashed line = maternal; solid = normal adult). Lym-
phocyte pyruvate kinase expression, but not LDH expression, is sub-
stantially reduced during pregnancy.
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kocytes from normal pregnant women, but not those
of pre-eclampsia patients, with respect to those of
non-pregnant women (data not shown). Hence,
pyruvate kinase is reduced in expression and enzy-
matic function in normal pregnancy.
Given the highly significant differences in pyru-
vate kinase expression and activity in the leukocytes
of non-pregnant women, normal pregnant women,
and those with pre-eclampsia, we assessed intracel-
lular pyruvate concentrations. We developed a novel
fluorescence assay for pyruvate of high sensitivity
and specificity for use with small volumes of natural
human biological specimens.34 Using this assay, we
measured the number of picomoles of pyruvate per
106 cells in cell extracts. To calculate the intracellular
pyruvate concentration, an estimate of cell volume
is required. We used PBMCs because there was a
limited amount of blood available for studies and
purified CD3+ cells yielded similar values in preli-
minary experiments. The volume of lymphocytes
has been determined to be 210 lm3.37 The volume
of small monocytes is 332 mm3, whereas that of
large monocytes is 380 lm3.38 As large monocytes
make up 2 ⁄ 3 of the total monocyte population,38 the
average monocyte volume is approximately
364 lm3. As the ratio of lymphocytes to monocytes
is 3:1 for non-pregnant and normal pregnant
women,39,40 the average peripheral blood mononu-
clear cell volume is roughly 249 lm3 for leukocytes
from non-pregnant women. As cell counts were per-
formed for all samples before extraction, variations
in the leukocyte numbers during pregnancy40 do not
affect our results. In addition, previous studies have
shown that the mean cell volume of leukocytes is
not affected by pregnancy.41,42 Based upon this
information, we calculated the intracellular pyruvate
concentrations in cells from non-pregnant, pregnant,
and pre-eclamptic women. As shown in Fig. 6, the
intracellular pyruvate concentration in leukocytes
from non-pregnant women is 1.58 mm, which is
substantially greater than that of samples from preg-
nant women (0.95 mm). Pyruvate levels in leuko-
cytes of pre-eclamptic women, again, track with
pyruvate kinase expression and activity and are
higher. As these means represent good measures of
the underlying population means, these differences
in pyruvate concentration may be sufficient to affect
Ca2+ signaling in cells.27
Calcium Signaling
If leukocyte function is affected by the pyruvate
kinase expression level, it may be possible to manip-
ulate cell signaling by changing pyruvate levels. As
Ca2+ experiments are performed over a short period
of time, we required a model system in which pyru-
vate levels could be easily altered. As preliminary
experiments showed that exogenous pyruvate could
quickly alter the intracellular level of pyruvate in
human Jurkat T cells, we used this as a model for
leukocyte signaling. (Similarly, washing Jurkat cells
in a pyruvate-free medium rapidly washes out intra-
cellular pyruvate.) To reduce pyruvate levels, phen-
ylalanine, a pyruvate kinase inhibitor was
(a) (b)
Fig. 3 Summary of flow cytometry studies of CD3+ lymphocytes (a) and neutrophils (b) from non-pregnant (open bars), pregnant (gray bars), and
pre-eclamptic (black bars) women. Panel a: Pyruvate kinase expression is reduced in lymphocytes from pregnant women in comparison with non-
pregnant women (P = 0.00001). Pyruvate kinase expression in cells from pre-eclampsia patients was significantly elevated in comparison with nor-
mal pregnant patients (P = 0.00046), but not non-pregnant women. Ten individuals in each category were studied. No significant differences are
detected in lactate dehydrogenase levels. Panel b: Maternal peripheral blood neutrophils have significantly less pyruvate kinase than neutrophils
from both non-pregnant women (0.000037) as well as women with pre-eclampsia (0.0036). Eight non-pregnant women were studied. Nine normal
pregnant women and nine pre-eclampsia patients were studied. As noted earlier for lymphocytes, no significant effect was noted for lactate dehy-
drogenase. Error bars represent the S.D.
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employed.43 To study Ca2+, we labeled Jurkat cells
with the dyes Fluo-4 and Fura Red, as described in
the Materials and Methods section. The Fluo-4 ⁄ Fura
Red ratio was measured as an indicator of intracellu-
lar Ca2+ concentration. In unstimulated lympho-
cytes, pyruvate addition enhanced Ca2+ levels,
whereas addition of phenylalanine, reduced Ca2+
levels (Fig. 7); although these changes were rela-
tively small, they were statistically significant. To test
leukocyte activation in this model, PHA stimulation
was employed, which leads to an increase in intra-
cellular Ca2+ as judged by the Fluo-4 ⁄ Fura Red ratio
(P < 0.00005; Fig. 8). PHA-stimulated cells exhibited
a decrease in Ca2+ in the presence of phenylalanine
and an increase in the presence of pyruvate (Fig. 8).
Thus, exogenous factors affecting pyruvate influence
the Ca2+ signaling apparatus of Jurkat cells.
Discussion
In the present study, we have demonstrated that
pyruvate kinase expression is reduced in leukocytes
from normal pregnant women in comparison with
non-pregnant women. In addition, leukocyte pyru-
vate kinase expression is higher in women with
pre-eclampsia than in normal pregnant women. The
biochemical significance of a change in enzyme
expression depends in complex fashion upon the
chemical properties of its reaction mechanism and
reaction network. For example, using in vitro sys-
tems, a four- to fivefold increase in phosphofructoki-
nase expression has no effect on glycolytic flux or
cell growth.44,45 However, similar changes in pyru-
vate kinase expression dramatically alter carbon flux
Fig. 4 Flow cytometry histograms of pyruvate kinase labeling of
human CD3+ lymphocytes are shown. Cells were untreated (control) or
treated with LPS (100 ng ⁄ mL, 30 min). Isotype controls are shown on
the left-hand side. No differences in pyruvate kinase levels could be
noted in the presence of LPS.
Fig. 5 Pyruvate kinase activity assay. Pyruvate kinase activity was measured using phosphoenolpyruvate as substrate and coupling pyruvate
production to the disappearance of NADH, which can be quantified using fluorescence detection.
Fig. 6 Evaluation of intracellular pyruvate concentrations. Intracellular
pyruvate concentrations were determined by measuring pyruvate lev-
els in cell extracts then correcting for cell volume. The pyruvate con-
centration in PBMCs from non-pregnant women (1.58 ± 0.22 mM;
mean ± S.E.M.; n = 8) was significantly higher than that of pregnant
women (0.95 ± 0.11 mm; n = 11) (P = 0.01). The pyruvate concentra-
tion in cells from pre-eclamptic patients (1.45 ± 0.19; n = 10) was sig-
nificantly higher than that of normal pregnant women (P < 0.05). As
indicated by the standard error of the means, these values are a good
measure of the underlying population means, thus supporting the pro-
posed mechanistic contribution to signaling.
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and cell growth.46,47 Pyruvate kinase is a highly reg-
ulated enzyme catalyzing an irreversible step of gly-
colysis that is associated with a large decrease in free
energy.48 Pyruvate kinase is also at a unique bio-
chemical ‘choke-point’ in metabolism, which is a
key factor regarding its importance in cancer cell
growth.49 To illustrate the functional importance of
our observations, we have explored changes in pyru-
vate kinase activity and intracellular pyruvate con-
centrations in leukocytes from non-pregnant
women, normal pregnant women, and women with
pre-eclampsia. The findings suggest that a roughly
twofold change in pyruvate kinase expression is
associated with a similar change in intracellular
pyruvate concentration.
Our measurements of intracellular pyruvate cou-
pled with estimates of leukocyte cell volume suggest
an intracellular pyruvate concentration of 1 mm.
As neutrophils and lymphocytes contain relatively
few mitochondria and rely primarily upon aerobic
glycolysis for energy production,50,51 mitochondrial
pyruvate catabolism is reduced in these cells, which
may contribute to higher intracellular pyruvate con-
centrations. Furthermore, our experimental assess-
ments of intracellular pyruvate concentration are
similar to estimates of perimembrane pyruvate levels
provided by others.27,52 However, as washing proto-
cols and the requirement of correcting for extracellu-
lar pyruvate in extracts complicate published
estimates of intracellular pyruvate concentrations,
we sought to more accurately determine this value.
Using newly developed methods of greater sensitiv-
ity, this study provides the first direct measurements
of intracellular pyruvate in immune cells, although
the values are considered to be estimates. Nonethe-
less, the intracellular concentration of pyruvate in
leukocytes from normal pregnant women is consid-
erably lower than that of cells from non-pregnant
women.
Signaling Strength
Recently, Bakowski and Parekh27 have shown that
pyruvate concentrations of roughly 1 mm increase
store-operated Ca2+ entry by inhibiting Ca2+-medi-
ated inactivation of these channels (Fig. 9). These
findings are important because: (i) they were
observed at physiologically relevant voltages and (ii)
substantial differences in fast CRAC channel inacti-
vation are observed in the range of pyruvate concen-
trations associated with leukocytes from pregnant
and non-pregnant women. Thus, the differences in
leukocyte pyruvate kinase expression of normal
pregnant and non-pregnant women would be antici-
pated to influence CRAC channel signaling thereby
blunting signal strength during pregnancy. However,
Fig. 7 Effect of pyruvate and phenylalanine, a pyruvate kinase inhibi-
tor, on the Fluo-4 ⁄ Fura Red ratio (a measure of intracellular Ca2+) in
unstimulated Jurkat cells. The Fluo-4 ⁄ Fura Red ratio is listed at the
ordinate (mean ± S.D.). Experiments were performed as described in
the Materials and Methods. Phenylalanine, a pyruvate kinase inhibi-
tor,43 is known to perturb the concentration of metabolites in Jurkat
cells.78 At 6 mM, phenylalanine significantly reduced the Fluo-4 ⁄ Fura
Red ratio. On the other hand, addition of pyruvate to cells promoted
an increase in the Fluo-4 ⁄ Fura Red ratio. Although significant, these
changes were not dramatic and required multiple repetitions to reach
these high levels of significance (n = 10).
Fig. 8 Effect of pyruvate and phenylalanine on the Fluo-4 ⁄ Fura Red
ratio (mean ± S.D.) in stimulated Jurkat cells. In the first three columns,
cells were activated using PHA. Addition of phenylalanine promoted a
decrease in the Fluo-4 ⁄ Fura Red ratio, whereas the addition of pyru-
vate promoted an increase in the Fluo-4 ⁄ Fura Red ratio. Untreated
cells are shown on the right-hand side for comparison (n = 10).
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it remains possible that pyruvate may also act
through other Ca2+ channels53 to influence signal
transduction during pregnancy.
Using Jurkat cells, a model human T lymphocyte,
to assess the role of pyruvate kinase in signaling, we
have manipulated pyruvate levels by adding high
concentrations of exogenous pyruvate, which is able
to enter these cells, and the pyruvate kinase inhibi-
tor phenylalanine. We observed that experimentally
induced reductions in pyruvate concentrations
diminish Ca2+ levels, whereas an elevation of pyru-
vate concentration also elicits an increase in intracel-
lular Ca2+ levels. These findings are consistent with
our proposed role of pyruvate kinase in Ca2+ signal-
ing.
Signal strength, including Ca2+ signaling strength, is
a key factor in determining the differentiation of
CD4+ T cells into Th1 and Th2 cells.54,55 As a result of
reduced intracellular pyruvate levels in leukocytes,
cells from normal pregnant women would be
expected to exhibit a reduction in the Th1 ⁄ Th2
ratio. This is consistent with prior studies, suggesting a
reduction in the Th1 ⁄ Th2 ratio during pregnancy.6–8
As CRAC channels are important in many leukocyte
populations,28 this mechanism may contribute to
Ca2+-sensitive leukocyte-activating pathways of
monocytes, neutrophils, and other cell types. As the
NADPH oxidase is activated in granule membranes of
neutrophils,56 our model suggests that at low signal
levels (e.g., normal pregnancy) Ca2+-dependent
degranulation is reduced, thereby enhancing intracel-
lular oxidant levels30,57 and decreasing extracellular
release14,15, whereas higher signal levels (e.g., cells
from non-pregnant individuals) would promote
greater NADPH oxidase delivery to the plasma mem-
brane and extracellular oxidant release.
Fig. 9 Proposed mechanism of pyruvate-
mediated influence on cell growth and immu-
nologic modifications. Pyruvate is produced
by pyruvate kinase, the final enzyme of glycol-
ysis. When pyruvate kinase levels are
depressed at this rate-limiting step of glycoly-
sis, upstream glycolytic phosphometabolite
intermediates accumulate to higher levels.
Higher levels of glycolytic intermediates sup-
port the synthesis of carbohydrates, nucleic
acids, amino acids, and lipids, as indicated in
the diagram. Pyruvate promotes Ca2+ signal-
ing by inhibiting the negative Ca2+ feedback at
the CRAC channel.27 Ca2+ directly influences
NFAT. However, when pyruvate levels are
reduced, signaling is reduced.
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Leukocytes from patients with pre-eclampsia had a
higher intracellular pyruvate concentration than that
of the same cells of normal pregnant women. It can
be anticipated that the increased intracellular con-
centration of pyruvate also leads to increased Ca2+
levels. Such findings have been previously reported
for women with pre-eclampsia.31,32 This may be a
contributory factor in the modified leukocyte proper-
ties associated with pre-eclampsia including
increased levels of pro-inflammatory cytokines,
enhanced reactive oxygen metabolite production,
nuclear translocation of NF-jB, and enhanced sur-
face CD11b, CD11a, CD49b expression.29,30,33
As described earlier, significant differences have
been found in leukocyte pyruvate kinase levels in
non-pregnant and pregnant women. It seems possi-
ble that serum levels of pyruvate or phenylalanine
might contribute to the measured pyruvate kinase
activity and pyruvate levels. For non-pregnant and
normal pregnant women, serum pyruvate levels
have been found to be 0.04–0.20 and 0.042–
0.09 mm, respectively.58,59 Moreover, serum phenyl-
alanine levels of 0.06–0.24 and 0.03–0.10 mm have
been found for non-pregnant and normal pregnant
women, respectively.60–64 Thus, in surveying studies
in this field, there are no significant differences in
pyruvate or phenylalanine levels in non-pregnant
and pregnant women. Thus, the differences we have
observed cannot be accounted for by serum levels of
pyruvate or phenylalanine.
Potentially Related Metabolic Pathways
In contrast to many glycolytic enzymes, pyruvate
kinase action is irreversible.48 In some cell types,
pyruvate levels could be affected by enzymes
involved in gluconeogenesis; specifically, pyruvate
carboxylase and phosphoenolpyruvate carboxykinase.
During gluconeogenesis, pyruvate carboxylase partic-
ipates in the conversion of pyruvate to
phosphoenolpyruvate. It is unlikely that differences
in pyruvate carboxylase levels affected the measured
and calculated pyruvate concentrations. First, pyru-
vate kinase and pyruvate carboxylase are prevented
by the signaling apparatus from functioning at the
same time to prevent a futile cycle.65 Second, circu-
lating leukocytes express extremely low levels of this
enzyme.66 Thus, this enzyme is unlikely to be a sig-
nificant contributor to our findings.
In another step of gluconeogenesis,
phosphoenolpyruvate carboxykinase converts oxalo-
acetate to phosphoenolpyruvate. We used an anti-
human pyruvate carboxylase (PCK-1) antibody
(Novus Biologicals, Littleton, CO, USA) to measure
the expression of this molecule by leukocytes. We
could not detect the expression of this enzyme in
leukocytes using flow cytometry (data not shown).
Therefore, this enzyme cannot interfere with the
experiments reported herein. These observations fur-
ther support our conclusions.
Potentially Related Disease Pathways
Our proposed mechanism also finds support in previ-
ous clinical studies. For example, conventional lac-
tate-based peritoneal dialysis solutions (L-PDS) have
been employed in continuous ambulatory peritoneal
dialysis for many years. It has been demonstrated that
L-PDS solutions reduce leukocyte cytokine production
(TNF-a and IL-1b), chemotaxis, and oxidant release as
well as mesothelial cell proliferation.67,68 Use of L-
PDS is associated with complications such as peritoni-
tis and peritoneal membrane perforations, which are
minimized by using pyruvate-based peritoneal dialysis
solutions (P-PDS).67,68 As extracellular pyruvate may
affect signaling, our mechanistic model may account
for these descriptive clinical findings.
Alterations in pyruvate kinase levels have also
been noted in neutrophils from patients following
polytrauma.69 A staggering 600-fold increase in
pyruvate kinase activity was noted in neutrophils,
suggesting that pyruvate kinase is no longer a rate-
limiting step in pyruvate production. Neutrophil acti-
vation, as judged by oxidant release, is greatly
enhanced in these cells, as our hypothetical mecha-
nism would suggest.
Additional support for our hypothesis can be
found in sepsis. In healthy individuals, peripheral
blood pyruvate levels are 0.04–0.08 mm. However,
during sepsis these levels climb to 0.4 mm.70 As
higher serum levels reduce the diffusion potential of
pyruvate across the cell membrane, pyruvate will
increase within cells, thus causing more robust stim-
ulation of TNF-a production, as seen during sepsis.
Thus, our model is consistent with previous clinical
investigations from other laboratories.
A Model for the Glycolytic Regulation and Further
Consideration of its Implications
We have used fluorescence microscopy, Western
blotting, flow cytometry, activity measurements, and
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intracellular pyruvate determinations to confirm the
reduced levels of cytosolic pyruvate kinase observed
in leukocytes from normal pregnant women.
Although Carboné et al.71 did not observe these
changes in pyruvate kinase activity, their results
were confounded by the use of detergents for
enzyme extraction, which promote enzyme denatur-
ation and the release of mitochondrial pyruvate
kinase activity.72 Fig. 9 shows an integration of the
glycolytic and signaling pathways that illustrates the
principles described earlier. Glycolytic phosphome-
tabolite intermediates enter the hexosamine biosyn-
thesis pathway, the hexose monophosphate shunt,
and the serine family biosynthesis pathways. When
the final step of glycolysis mediated by pyruvate
kinase is reduced, glycolytic phosphometabolite
intermediates accumulate in the cytoplasm, which
supports the synthesis of sugars, nucleotides, amino
acids, and lipids. In tumor cell biology, a reduction
in pyruvate kinase activity is essential in supporting
cell growth.73 The potential role of pyruvate kinase
expression levels in cell growth in normal and pre-
eclamptic pregnancies awaits further study. As illus-
trated at the bottom of this figure and discussed pre-
viously, when pyruvate levels are reduced, as in
normal pregnancy, rising intracellular Ca2+ levels
feedback to decrease CRAC activity thereby reducing
further Ca2+ entry.
Our findings are particularly exciting because they
describe glycolytic enzyme changes in leukocytes
during pregnancy that may provide a mechanism
contributing to immunoregulation. It will be impor-
tant to determine whether the changes in intracellu-
lar pyruvate concentrations occur in early pregnancy
and whether the increase observed in pre-eclampsia
is detectable before the diagnosis of the disease. If
this is the case, then intracellular pyruvate concen-
trations may have predictive value. Longitudinal
studies are required to test this hypothesis. Similarly,
it is important to determine whether such findings
are specific to pre-eclampsia or whether they can be
observed in other complications of pregnancy. We
have previously reported changes in the phenotypic
and metabolic characteristics of neutrophils and
monocytes in other obstetrical syndromes, such as
preterm labor, preterm PROM, and SGA.74–77 One
possibility that cannot be excluded is that the gen-
eral mechanisms described herein apply to more
than one complication of pregnancy and that it may
be observed not only in the maternal compartment,
but also the fetal compartment. Furthermore, it may
be possible to design drugs that mildly suppress
pyruvate kinase activity to diminish pro-inflamma-
tory signaling, such as that observed during pre-
eclampsia. In a subsequent article, we explore this
possibility.
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Figure S1. Western blots of leukocyte extracts
from non-pregnant women (left) and normal preg-
nant women (right) is shown. Experiments were
performed as described in the Materials and Meth-
ods. It is clear that pyruvate kinase expression is
reduced during normal pregnancy.
Figure S2. A scatter plot of flow cytometry data
of pyruvate kinase expression in lymphocytes from
non-pregnant women, pregnant women, and
women with pre-eclampsia is shown.
Please note: Wiley-Blackwell are not responsible
for the content or functionality of any supporting
materials supplied by the authors. Any queries
(other than missing material) should be directed to
the corresponding author for the article.
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